Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis

Bibliographic Details
Title: Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Authors: Taeksun Song, Myungsun Lee, Han-Seung Jeon, Yumi Park, Lori E. Dodd, Véronique Dartois, Dean Follman, Jing Wang, Ying Cai, Lisa C. Goldfeder, Kenneth N. Olivier, Yingda Xie, Laura E. Via, Sang Nae Cho, Clifton E. Barry III, Ray Y. Chen
Source: EBioMedicine, Vol 2, Iss 11, Pp 1627-1633 (2015)
Publisher Information: Elsevier, 2015.
Publication Year: 2015
Collection: LCC:Medicine
LCC:Medicine (General)
Subject Terms: Mitochondrial toxicity, Adverse events, Linezolid, Tuberculosis, Drug resistant, Therapeutic drug monitoring, Medicine, Medicine (General), R5-920
More Details: Long-term linezolid use is limited by mitochondrial toxicity-associated adverse events (AEs). Within a prospective, randomized controlled trial of linezolid to treat chronic extensively drug-resistant tuberculosis, we serially monitored the translational competence of mitochondria isolated from peripheral blood of participants by determining the cytochrome c oxidase/citrate synthase activity ratio. We compared this ratio with AEs associated with mitochondrial dysfunction. Linezolid trough concentrations were determined for 38 participants at both 600 mg and 300 mg doses. Those on 600 mg had a significantly higher risk of AE than those on 300 mg (HR 3·10, 95% CI 1·23–7 · 86). Mean mitochondrial function levels were significantly higher in patients before starting linezolid compared to their concentrations on 300 mg (P = 0·004) or 600 mg (P 2 μg/ml developing an AE related to mitochondrial toxicity, whether on 300 mg or 600 mg. Therapeutic drug monitoring may be useful to prevent the development of mitochondrial toxicity associated with long-term linezolid use.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2352-3964
Relation: http://www.sciencedirect.com/science/article/pii/S2352396415301663; https://doaj.org/toc/2352-3964
DOI: 10.1016/j.ebiom.2015.09.051
Access URL: https://doaj.org/article/7beaa75555b04827aa0e2b13b0e0cec4
Accession Number: edsdoj.7beaa75555b04827aa0e2b13b0e0cec4
Database: Directory of Open Access Journals
More Details
ISSN:23523964
DOI:10.1016/j.ebiom.2015.09.051
Published in:EBioMedicine
Language:English